Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- New trial Spotlight
Multiple solid tumors
Phase I/II Trial of AZD6750, CD8-guided IL-2 fusion protein, in advanced solid tumors
This trial evaluates the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD6750 as a single agent or in combination with rilvegostomig—a Tigit and PD-1 bispecific mAb—in adult participants…
NCT07115043 First-in-human - Trial result Spotlight
Head and neck cancer
Sequential Pembrolizumab (PD-1) Tops Concurrent for 4-yr Control in LA-HNSCC
Pembrolizumab—an anti-PD-1 antibody—was tested with definitive chemoradiation (CRT: weekly cisplatin 40 mg/m² + 70 Gy RT) either concurrently (start 1 wk pre-CRT) or sequentially (start 2 wks post-CRT) in a…
NCT02777385 - Trial result Spotlight
Melanoma
FMT + Anti-PD-1 Delivers 65% ORR and mPFS 29.6 mo in Frontline Melanoma
The MIMic phase I trial (multicenter; NCT03772899) gave a single oral fecal-microbiota transplant (healthy-donor stool) followed by standard anti-PD-1 as first-line therapy for advanced melanoma (n=20). ORR was 65%…
NCT03772899 - New trial Spotlight
Breast cancer
Phase II STEMVAC DNA Vaccine Targeting Breast Cancer Stem Cell Proteins
This phase II trial investigates STEMVAC in combination with standard endocrine therapy plus a CDK4/6 inhibitor or capecitabine in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.…
NCT07112053 Exploratory - New trial Spotlight
Prostate cancer
Phase 2 Tarlatamab Study: DLL3/CD3 bispecific antibody in metastatic prostate cancer.
This Phase 2 trial evaluates tarlatamab, a DLL3 and CD3 directed bispecific monoclonal antibody, in patients with metastatic, DLL3‐positive prostate cancer that is refractory or relapsed after prior treatment (where…
NCT07111507 Exploratory - New trial Spotlight
Bladder and urothelial cancer
Phase 2/3 Izalontamab Brengitecan EGFR/HER3 bispecific ADC in metastatic urothelial cancer
This study, sponsored by Bristol-Myers Squibb and conducted at multiple international sites, is evaluating a novel ADC targeting EGFR/HER3 (BMS-986507) against standard platinum-based chemotherapy (cisplatin,…
NCT07106762 Registrational - Trial result Spotlight
Brain and CNS tumors
DOC1021 Autologous DC Vaccine Hits 88% 12-mo OS in IDH-wt GBM (Phase I)
DOC1021 is an autologous dendritic-cell vaccine loaded with each patient’s tumor lysate plus amplified tumor mRNA and injected near deep cervical nodes with weekly peg-IFN after chemoradiation. In a single-arm…
NCT04552886 - Trial result Spotlight
Uterine (endometrial) cancer
PARP Inhibitor Rucaparib Extends PFS to 28 mo in Metastatic/Recurrent Endometrial Cancer
Rucaparib, an oral PARP1/2 inhibitor that exploits tumor DNA-repair defects, was tested as switch-maintenance after 1–2 chemotherapy lines in a double-blind Phase II trial (NCT03617679). Seventy-nine patients with…
NCT03617679 - Trial result Spotlight
Non-small cell lung cancer
Pralsetinib (Selective RET TKI): ctDNA Clearance Flags 12-mo + PFS in RET-Fusion NSCLC
Pralsetinib, an oral CNS-penetrant RET tyrosine-kinase inhibitor, was evaluated in a single-arm prospective biomarker study of 21 Chinese patients with advanced RET-fusion NSCLC (Phase 2 ARROW, NCT03037385). Baseline…
NCT03037385 - Trial result Spotlight
Myeloproliferative neoplasms
Avapritinib (KIT D816V) Beats Midostaurin/Cladribine on OS in AdvSM
Avapritinib, a selective KIT D816V inhibitor, was compared via IPTW-adjusted external controls to midostaurin (multikinase/KIT) or cladribine (purine analog) using EXPLORER/PATHFINDER trial patients (n=176) versus…
- Trial result Spotlight
Bladder and urothelial cancer
TAR-200 Intravesical Gemcitabine Device Posts 82% CR in BCG-Unresponsive CIS (Phase IIb)
TAR-200 is an osmotic intravesical drug-releasing system for sustained gemcitabine delivery; in SunRISe-1, BCG-unresponsive high-risk NMIBC received TAR-200 alone, TAR-200+cetrelimab (PD-1), or cetrelimab alone…
- New trial Spotlight
Prostate cancer
Phase 1b pTVG-HP DNA vaccine and sasanlimab PD-1 inhibitor in oligometastatic prostate cancer
This study evaluates the combination of an investigational pTVG-HP DNA vaccine (targeting prostatic acid phosphatase) and sasanlimab, a PD-1 blocking monoclonal antibody, with radiation therapy in non-castrate,…
NCT07090148 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase II Trial: Dato-DXd, TROP2-directed ADC in advanced NSCLC
This Phase II study at AstraZeneca and select centers evaluates three sub-studies in advanced or metastatic NSCLC. It tests rilvegostomig—a Tigit and PD-1 bispecific mAb—with ramucirumab, a VEGFR2-directed antibody,…
NCT07098338 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 2b trial of Visugromab, anti‐GDF15 monoclonal antibody, in metastatic NSCLC
CatalYm GmbH sponsors a multi-part Phase 2b study comparing visugromab with pembrolizumab, pemetrexed, and carboplatin versus placebo plus standard immunochemotherapy. The trial targets first-line treatment for…
NCT07098988 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 2/3 trial of BMS-986504, a selective PRMT5 inhibitor, in metastatic pancreatic cancer.
The study evaluates safety and efficacy of BMS-986504 when combined with gemcitabine and nab-paclitaxel versus standard chemo plus placebo in a randomized design. It enrolls treatment-naïve patients with metastatic…
NCT07076121 Registrational - New trial Spotlight
Pancreatic cancer
Phase 1 Trial of OMO-103, a Myc Inhibitor, in Pancreatic Cancer
This early Phase 1 trial is assessing OMO-103, a dominant-negative MYC inhibitor (Omomyc miniprotein) that disrupts MYC–MAX, in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.…
NCT07089940 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 1B SONALA-001 Protoporphyrin IX ROS activator with MRgFUS for recurrent glioblastoma
This Phase 1B study, sponsored by Mayo Clinic, evaluates the safety, optimal dosing, and preliminary effectiveness of SONALA-001 (a Protoporphyrin IX ROS activator small molecule) given with MR-guided focused…
NCT07076472 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 1 trial of GPC2 CAR-T cells targeting GPC2 in pediatric CNS embryonal tumors
This single-site, open-label Phase 1 trial at Stanford University evaluates feasibility, safety, and preliminary activity of autologous GPC2 CAR-T cells delivered via intracerebroventricular infusions in children and…
NCT07087002 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 1 Trial of M032 IL-12 Producing HSV Oncolytic Virus for Diffuse Midline Glioma
This trial led by MD Anderson Cancer Center evaluates a single intratumoral injection of M032, an IL-12 producing HSV oncolytic virus, in pediatric and adult patients with diffuse midline glioma following standard…
NCT07076498 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 1 CHAMP1ON: Nivolumab PD-1 Inhibitor for Pediatric High-Grade Glioma
University of Florida is conducting a Phase 1 trial to evaluate safety and feasibility of adjuvant and neoadjuvant ex vivo hematopoietic stem cells (exHSCs), an investigational cell therapy intended to support immune…
NCT07031765 First-in-human - New trial Spotlight
Multiple myeloma
Phase I Trial of GB1211 (Oral Galectin-3 Inhibitor) in Multiple Myeloma
This study is designed to evaluate the safety, tolerability, and optimal dosing of selvigaltin, a galectin-3 blocker, when combined with daratumumab-hyaluronidase, carfilzomib, and dexamethasone in patients with…
NCT07082270 First-in-human - New trial Spotlight
Head and neck cancer
Phase II Trial of Ivonescimab, a PD-1/VEGF bispecific antibody in resectable head and neck cancer
This phase II study by the University of Michigan Rogel Cancer Center evaluates neoadjuvant ivonescimab in patients with stage II-IV resectable head and neck cancer. Ivonescimab, a bispecific antibody targeting PD-1…
NCT07094685 Exploratory - New trial Spotlight
Stomach and esophageal cancer
Phase 3 Study of Ifinatamab Deruxtecan, a B7-H3 directed Topo1 toxin ADC, in ESCC
Researchers at Daiichi Sankyo are assessing ifinatamab deruxtecan versus investigator’s choice chemotherapy in a randomized, open-label Phase 3 trial for patients with unresectable advanced or metastatic esophageal…
NCT06644781 Registrational - New trial Spotlight
Multiple solid tumors
Phase 1 ALX2004 Antibody-Drug Conjugate Targeting EGFR in Advanced Solid Tumors
This phase 1 study evaluates ALX2004, an antibody drug conjugate targeting EGFR, in an open-label, multicenter trial featuring dose escalation, exploration, and expansion phases to determine the recommended phase 2…
NCT07085091 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 trial of ERAS-4001, a pan-KRAS-targeted agent
This first-in-human open-label study evaluates the safety, tolerability, and preliminary efficacy of ERAS-4001 given orally as monotherapy and in combination with another investigational drug in a dose optimization…
NCT07021898 First-in-human - Trial result Spotlight
Lymphoma
Finite‑Course Venetoclax (BCL‑2) Delivers 36 mo Median PFS in Relapsed Waldenström Macroglobulinemia
Venetoclax, an oral BCL‑2 inhibitor, was given at 200→800 mg daily for up to 2 years in a single‑arm phase 2 trial (NCT02677324) of 32 previously treated WM patients (median follow‑up 81 mo). Median progression‑free…
NCT02677324 - Trial result Spotlight
Lymphoma
Calibrated CD19‑1XX CAR T Achieves 75% CR with Only 4% Grade ≥3 CRS in r/r LBCL
19(T2)28z‑1XX, a CD19 CAR T cell engineered for “just‑right” 1XX signaling, was evaluated in the first‑in‑human phase I dose‑escalation/expansion study NCT04464200. Twenty‑eight adults with relapsed/refractory large…
NCT04464200 - Trial result Spotlight
Multiple solid tumors
BHV‑1510 Trop2‑TopoIx ADC Shrinks Tumors in 6/6 Patients; FGFR3 ADC BHV‑1530 Enters Clinic
BHV‑1510 is a Trop2‑targeted antibody—drug conjugate armed with Biohaven’s proprietary TopoIx topoisomerase I payload; in the first Phase 1 cohorts (monotherapy and in combo with the anti‑PD‑1 antibody cemiplimab)…
- New trial Spotlight
Non-small cell lung cancer
Phase 2/3 trial of BMS-986504, a selective MTA-cooperative PRMT5 inhibitor in metastatic NSCLC
This randomized study compares BMS-986504 combined with pembrolizumab and chemotherapy versus placebo regimens in first-line metastatic non-small cell lung cancer patients with homozygous MTAP deletion. BMS-986504…
NCT07063745 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase I CVHNLC mRNA immunotherapy plus pembrolizumab PD-1 inhibitor study in metastatic sqNSCLC
This open-label, first-in-human trial by CureVac evaluates safety and tolerability of investigational CVHNLC—an mRNA therapy intended to trigger anti-tumor immune responses—in combination with pembrolizumab and, in…
NCT07073183 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.